Aethlon Medical (AEMD) regains Nasdaq $1.00 bid price compliance

Aethlon Medical (AEMD) announced it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Rhea-AI Filing Summary

Aethlon Medical (AEMD) announced it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq confirmed on November 5 that the matter is closed.

The company had received a notice on October 16 that its common stock had closed below the $1.00 minimum for 30 consecutive business days. Regaining compliance required maintaining a closing bid of at least $1.00 per share for ten consecutive business days, which the company achieved.

This update removes the immediate listing deficiency and keeps AEMD’s shares trading on Nasdaq, preserving market visibility and liquidity associated with that venue.

Insights

Regulatory Compliance Analyst

Aethlon regained Nasdaq bid-price compliance; immediate delisting risk tied to this issue is removed.

The company received Nasdaq confirmation on November 5, 2025 that it regained compliance with the minimum bid price requirement. This follows a prior notice on October 16, 2025 citing noncompliance after 30 consecutive days below $1.00. Compliance required maintaining a closing bid of at least $1.00 for ten straight business days. Nasdaq considers the matter closed.

This resolves a listing deficiency that can cascade into trading and liquidity disruptions if unaddressed. The action preserves access to The Nasdaq Capital Market and the associated visibility and institutional eligibility that listing provides. No other deficiencies are disclosed here.

Key items to watch: continued adherence to Nasdaq rules, especially the bid-price threshold and any future notices. The pivotal checkpoint already occurred by November 5, 2025; attention now shifts to maintaining compliance over time.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aethlon Medical (AEMD) announce?

The company regained compliance with Nasdaq’s minimum bid price requirement, and Nasdaq stated the matter is now closed.

What is Nasdaq’s minimum bid price requirement for AEMD?

A closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.

Why was AEMD previously non-compliant?

Its common stock closed below $1.00 for 30 consecutive business days as noted in a notice dated October 16, 2025.

When did Nasdaq confirm AEMD’s compliance?

Nasdaq confirmed compliance in a letter dated November 5, 2025.

What does this mean for AEMD’s listing?

AEMD remains listed on the Nasdaq Capital Market, with the prior deficiency matter closed.

Which market does AEMD trade on?

AEMD trades on the Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 09:15 AM Learn about SEC filing dates

false 0000882291 0000882291 2025-11-06 2025-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11555 Sorrento Valley Road, Suite 203 San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (619) 941-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		AEMD		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On November 5, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market.

As previously disclosed, on October 16, 2025, the Company received a letter from Nasdaq, notifying the Company that it was not in compliance with the Minimum Bid Price Requirement because the Company’s common stock, par value $0.001 (the “Common Stock”), had closed below the $1.00 per share minimum for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, the Common Stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.

In its letter dated November 5, 2025, Nasdaq indicated the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2025	Aethlon Medical, Inc.
	By:	/s/ James B. Frakes
	Name:	James B. Frakes Chief Executive Officer and Chief Financial Officer

3